Dr Kilian Kelly has approximately 15 years’ experience in pharmaceutical/biotechnology research and development, in both commercial and academic settings. His previous appointments include Senior Director, Drug Development at Biota Pharmaceuticals (NASDAQ: BOTA), Vice President, Regulatory and Clinical at Mesoblast Limited (ASX:MSB), and various regulatory affairs and project management positions with Kendle International (now INC Research), Amgen (NASDAQ: AMGN) and Astrazeneca (LSE: AZN). Dr Kelly holds a Masters in Pharmacy from Robert Gordon University, Aberdeen and a PhD in Pharmaceutical Sciences from Strathclyde University, Glasgow. He is a registered pharmacist and a member of the Royal Pharmaceutical Society, The Organisation for Professionals in Regulatory Affairs (TOPRA) and the Regulatory Affairs Professionals Society (RAPS).

Dr Macdonald has over 20 years’ experience and a track record of success in pharmaceutical and biotechnology businesses. His career history includes positions as Chief Executive Officer of Hatchtech Pty Ltd, Vice President of Business Development for Sinclair Pharmaceuticals Ltd, a UK-based specialty pharmaceuticals company, Vice President of Business Development for Connetics Corporation (Palo Alto, CA), and Vice President, Corporate Development for Stiefel Laboratories Inc, the largest independent dermatology company in the world and acquired by Glaxo Smith Kline in 2009 for £2.25b.

Dr Macdonald has also served as Vice President of Research and Development of F H Faulding & Co Ltd and CEO of Living Cell Technologies Ltd. His other positions have included non-executive director roles at iSonea Ltd, Telesso Technologies Ltd, Hatchtech Pty Ltd and Relevare Pharmaceuticals Ltd. Dr Macdonald currently serves as a member of the Investment Committee of UniSeed Management Pty Ltd.

Dr Macdonald holds a PhD in Biochemistry, Monash University, a Graduate Diploma in Business Administration, Swinburne University, and he is a member of the Licensing Executives Society.

Silvio Tiziani has played a key role in the establishment of Centre for Commercialisation of Regenerative Medicine (CCRM) Australia with the support of Canada’s CCRM, the Victorian Government and MTPConnect. Silvio is also Director, External Strategy and Planning at the Australian Regenerative Medicine Institute (ARMI). Silvio’s extensive knowledge of the research landscape is well utilised with his networks within the industry, international organisations and state and federal governments.

Silvio has extensive experience in private and public organisations, with a focus on laboratory-based services in government, private organisations, healthcare and research/academia.

In addition to qualifications that include a Bachelor of Science from Swinburne University and a Masters of Business Administration from Monash University, Silvio is also a graduate of the Australian Institute of Company Directors (GAICD). Silvio has extensive experience in financial analysis and budget management, business development, strategic planning and corporate governance along with strong interpersonal skills to lead staff.

Silvio also chairs the Ausbiotech Regenerative Medicine Advisory Group. Comprising leading representatives from industry and academia within the Australian regenerative medicine the Group provides specialist advice to Ausbiotech, Australia’s member-based biotechnology organisation, a peak body that promotes the global growth of Australian biotechnology.